RxDoctor Payments Data

Janet Bruce

Nurse Practitioner · Tucson, AZNPI 1639148323

Payments from drug & device makers

$1,029in general payments, 2019–2025

Across 41 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene USA, Inc.$149
  • Merck$98
  • AstraZeneca$88
  • Daiichi Sankyo Inc.$68
  • AbbVie$55
  • Pfizer$47
  • plus $525 from 20 others

What the payments were for

  • Food & beverage$99897%
  • Education$313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,029 in reported general payments places this provider in the 80th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$113,235
Medicare patients
183
Services billed
6,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax21$312,244
IbrancePalbociclib13$209,453
XareltoRivaroxaban46$46,089
EliquisApixaban28$32,382
Imatinib Mesylate12$2,202
Fluconazole18$2,158
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$848
Dexamethasone27$622
Anastrozole27$612
Letrozole23$589
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine19$531
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$443
Potassium Chloride19$371
Oxycodone Hcl20$354
Hydroxyurea16$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$55$312,24421 claims
PfizerIbrance, Eliquis$47$241,83541 claims
Johnson & JohnsonXarelto$31$46,08946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →